Loading...
The current generation of direct acting antivirals (DAAs), telaprevir and boceprevir, in combination with peginterferon and ribavirin (PEG/RBV) have demonstrated limited efficacy in patients with hepatitis C virus (HCV) genotype 1 infection who have experienced a previous null response to PEG/RBV. Sustained virologic response (SVR) has been approximately 30%, with associated high rates of resistance. Now, researchers have explored the efficacy of two next-generation DAAs with and without PEG/RBV in this patient population.
This phase IIa, industry-sponsored, randomized study involved 21 patients with previous null response to PEG/RBV (defined as <2 log HCV RNA drop from baseline at 12 weeks). Eleven patients received 60 mg daily of daclatasv…